文献速递临床试验与 GCP流行病学与生物统计

植入式与延长外部心电监测对缺血性卒中患者房颤检测的影响:PER DIEM随机临床试验

Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

在加拿大3家医院纳入300例近6个月内缺血性卒中且无已知房颤的患者,随机1:1接受植入式循环记录仪12个月监测或外部循环记录仪30天监测。8项预设次要结局中6项无显著差异。

要点

  • 缺血性卒中后无已知房颤者,植入式监测12个月房颤检出率显著高于外部监测30天。
  • 植入式组房颤检出15.3%,外部组4.7%,风险比3.29(95%CI 1.45至7.42)。
  • 两组复发性缺血性卒中、脑出血、死亡及器械相关严重不良事件无显著差异。

核心结论

  • 在缺血性卒中且无已知房颤的患者中,植入式心电监测12个月相比外部监测30天,12个月内房颤检出比例显著更高。
  • 需进一步研究比较两种监测策略相关的临床结局和相对成本效益。

研究设计与样本

  • 研究者发起的开放标签随机临床试验,在加拿大阿尔伯塔省2家大学医院和1家社区医院开展。
  • 植入式循环记录仪组150例,外部循环记录仪组150例,随访访视在30天、6个月和12个月。
  • 273例(91.0%)完成持续24小时以上的心脏监测,259例(86.3%)完成指定监测和12个月随访访视。

主要发现

  • 复发性缺血性卒中:植入式组5例(3.3%),外部组8例(5.3%),组间差异-2.0%(95%CI -6.6%至2.6%)。
  • 脑出血:两组各1例(0.7%),组间差异0%(95%CI -1.8%至1.8%)。
  • 死亡:两组各3例(2.0%),组间差异0%(95%CI -3.2%至3.2%)。
  • 器械相关严重不良事件:植入式组1例(0.7%),外部组0例(0%)。

临床怎么用

  • 对于近6个月内缺血性卒中且无已知房颤的患者,可考虑植入式心电监测12个月以提高房颤检出率。
  • 选择监测策略时需结合患者意愿、资源可及性及成本效益,并关注器械相关不良事件。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量300例,事件数较少,次要结局的组间比较置信区间较宽。
  • 研究仅纳入加拿大3家医院的患者,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The relative rates of detection of atrial fibrillation (AF) or atrial flutter from evaluating patients with prolonged electrocardiographic monitoring with an external loop recorder or implantable loop recorder after an ischemic stroke are unknown. OBJECTIVE: To determine, in patients with a recent ischemic stroke, whether 12 months of implantable loop recorder monitoring detects more occurrences of AF compared with conventional external loop recorder monitoring for 30 days. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, open-label, randomized clinical trial conducted at 2 university hospitals and 1 community hospital in Alberta, Canada, including 300 patients within 6 months of ischemic stroke and without known AF from May 2015 through November 2017; final follow-up was in December 2018. INTERVENTIONS: Participants were randomly assigned 1:1 to prolonged electrocardiographic monitoring with either an implantable loop recorder (n = 150) or an external loop recorder (n = 150) with follow-up visits at 30 days, 6 months, and 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the development of definite AF or highly probable AF (adjudicated new AF lasting ≥2 minutes within 12 months of randomization). There were 8 prespecified secondary outcomes including time to event analysis of new AF, recurrent ischemic stroke, intracerebral hemorrhage, death, and device-related serious adverse events within 12 months. RESULTS: Among the 300 patients who were randomized (median age, 64.1 years [interquartile range, 56.1 to 73.7 years]; 121 were women [40.3%]; and 66.3% had a stroke of undetermined etiology with a median CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category] score of 4 [interquartile range, 3 to 5]), 273 (91.0%) completed cardiac monitoring lasting 24 hours or longer and 259 (86.3%) completed both the assigned monitoring and 12-month follow-up visit. The primary outcome was observed in 15.3% (23/150) of patients in the implantable loop recorder group and 4.7% (7/150) of patients in the external loop recorder group (between-group difference, 10.7% [95% CI, 4.0% to 17.3%]; risk ratio, 3.29 [95% CI, 1.45 to 7.42]; P = .003). Of the 8 specified secondary outcomes, 6 were not significantly different. There were 5 patients (3.3%) in the implantable loop recorder group who had recurrent ischemic stroke vs 8 patients (5.3%) in the external loop recorder group (between-group difference, -2.0% [95% CI, -6.6% to 2.6%]), 1 (0.7%) vs 1 (0.7%), respectively, who had intracerebral hemorrhage (between-group difference, 0% [95% CI, -1.8% to 1.8%]), 3 (2.0%) vs 3 (2.0%) who died (between-group difference, 0% [95% CI, -3.2% to 3.2%]), and 1 (0.7%) vs 0 (0%) who had device-related serious adverse events. CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke and no prior evidence of AF, implantable electrocardiographic monitoring for 12 months, compared with prolonged external monitoring for 30 days, resulted in a significantly greater proportion of patients with AF detected over 12 months. Further research is needed to compare clinical outcomes associated with these monitoring strategies and relative cost-effectiveness. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02428140.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Buck BH, Hill MD, Quinn FR, et al. Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial. JAMA. 2021. PMID: 34061146. doi:10.1001/jama.2021.6128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。